Skip to main content

Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus

Pediatric Drugs volume 18, pages 181–195 (2016)Cite this article

Abstract

Systemic lupus erythematosus (SLE) is a rare, severe, multisystem autoimmune disorder. Childhood-onset SLE (cSLE) follows a more aggressive course with greater associated morbidity and mortality than adult-onset SLE. Its aetiology is yet to be fully elucidated. It is recognised to be the archetypal systemic autoimmune disease, arising from a complex interaction between the innate and adaptive immune systems. Its complexity is reflected by the fact that there has been only one new drug licensed for use in SLE in the last 50 years. However, biologic agents that specifically target aspects of the immune system are emerging. Immunosuppression remains the cornerstone of medical management, with glucocorticoids still playing a leading role. Treatment choices are led by disease severity. Immunosuppressants, including azathioprine and methotrexate, are used in mild to moderate manifestations. Mycophenolate mofetil is widely used for lupus nephritis. Cyclophosphamide remains the first-line treatment for patients with severe organ disease. No biologic therapies have yet been approved for cSLE, although they are being used increasingly as part of routine care of patients with severe lupus nephritis or with neurological and/or haematological involvement. Drugs influencing B cell survival, including belimumab and rituximab, are currently undergoing clinical trials in cSLE. Hydroxychloroquine is indicated for disease manifestations of all severities and can be used as monotherapy in mild disease. However, the management of cSLE is hampered by the lack of a robust evidence base. To date, it has been principally guided by best-practice guidelines, retrospective case series and adapted adult protocols. In this pharmacological review, we provide an overview of current practice for the management of cSLE, together with recent advances in new therapies, including biologic agents.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Riboldi P, Gerosa M, Moroni G, Radice A, Allegri F, Sinico A, et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity. 2005;38(1):39–45.

    CAS  PubMed  Article  Google Scholar 

  2. Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol. 2009;36(11):2539–46.

    PubMed  Article  Google Scholar 

  3. Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, et al. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus cohort. Arthritis Rheum. 2012;64(7):2356–65.

    PubMed  Article  Google Scholar 

  4. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):556–62.

    PubMed  Article  Google Scholar 

  5. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6(9):538–46.

    CAS  PubMed  Article  Google Scholar 

  6. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152(4):550–6.

    PubMed  Article  Google Scholar 

  7. Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus. 2006;15(8):515–20.

    CAS  PubMed  Article  Google Scholar 

  8. Ruperto N, Buratti S, Duarte-Salazar C, Pistorio A, Reiff A, Bernstein B, et al. Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis Care Res. 2004;51(3):458–64.

    Article  Google Scholar 

  9. Tucker LB, Uribe AG, Fernández M, Vilá LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314–22.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D, Cebecauer L, et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis. 2009;68(3):412–5.

    CAS  PubMed  Article  Google Scholar 

  11. Smith EM, Foster HE, Beresford MW. Adding to complexity: comorbidity in paediatric rheumatic disease. Rheumatology (Oxford). 2013;52(1):22–33.

    Article  Google Scholar 

  12. van Vollenhoven RF, Parodis I, Levitsky A. Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol. 2013;27(3):341–9.

    PubMed  Article  Google Scholar 

  13. Oelke K, Richardson B. Pathogenesis of lupus. Arthritis Rheum. 2002;47(3):343–5.

    PubMed  Article  Google Scholar 

  14. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301(1):5–8.

    CAS  PubMed  Article  Google Scholar 

  15. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci. 2003;100(5):2610–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36(8):481–90.

    CAS  PubMed  Article  Google Scholar 

  17. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008;29(1):150–64.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. Midgley A, McLaren Z, Moots RJ, Edwards SW, Beresford MW. The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2009;60(8):2390–401.

    CAS  PubMed  Article  Google Scholar 

  19. Bentham J, Vyse TJ. The development of genome-wide association studies and their application to complex diseases, including lupus. Lupus. 2013;22(12):1205–13.

    CAS  PubMed  Article  Google Scholar 

  20. Smith KD. Lupus nephritis: toll the trigger! J Am Soc Nephrol. 2006;17(12):3273–5.

    CAS  PubMed  Article  Google Scholar 

  21. Pisetsky DS. The origin and properties of extracellular DNA: from PAMP to DAMP. Clin Immunol. 2012;144(1):32–40.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. Midgley A, Thorbinson C, Beresford MW. Expression of toll-like receptors and their detection of nuclear self-antigen leading to immune activation in JSLE. Rheumatology (Oxford). 2012;51(5):824–32.

    CAS  Article  Google Scholar 

  23. Fernández-Castro M, Mellor-Pita S, Citores MJ, Muñoz P, Tutor-Ureta P, Silva L, et al. Common variable immunodeficiency in systemic lupus erythematosus. Semin Arthritis Rheum. 2007;36(4):238–45.

    PubMed  Article  Google Scholar 

  24. Jacob CO, Reiff A, Armstrong DL, Myones BL, Silverman E, Klein-Gitelman M, et al. Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum. 2007;56(12):4164–73.

    CAS  PubMed  Article  Google Scholar 

  25. Midgley A, Watson L, Beresford MW. New insights into the pathogenesis and management of lupus in children. Arch Dis Child. 2014;99(6):563–7.

    CAS  PubMed  Article  Google Scholar 

  26. Crispín JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):317–25.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  27. Crispin JC, Alcocer-Varela J. The role myeloid dendritic cells play in the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2007;6(7):450–6.

    CAS  PubMed  Article  Google Scholar 

  28. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33.

    CAS  PubMed  Article  Google Scholar 

  29. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48(5):1332–42.

    PubMed  Article  Google Scholar 

  30. Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166(1):6–10.

    CAS  PubMed  Article  Google Scholar 

  31. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.

    CAS  PubMed  Article  Google Scholar 

  32. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.

    CAS  PubMed  Article  Google Scholar 

  33. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.

    PubMed  PubMed Central  Article  Google Scholar 

  34. Morgan TA, Lloyd O, Heaf E, Smith E, Beresford MW. Application of the Systemic Lupus International Collaborating Clinics Classification (SLICC) criteria to the Juvenile-Onset Systemic Lupus Erythematosus nephritis cohort. Lupus. 2014;23:449–99.

    Article  Google Scholar 

  35. Lloyd O, Heaf E, Morgan T, Roberts C, McCann L, Beresford MW. A comparison of the American College of Rheumatology and the Systemic Lupus International Collaborating Clinics classification criteria using data from the UK Juvenile-Onset Systemic Lupus Erythematosus cohort study. Pediatr Rheumatol. 2013;11(Suppl 2):I2356.

    Article  Google Scholar 

  36. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630–40.

    CAS  PubMed  Article  Google Scholar 

  37. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004: development and initial validation of an updated version of the British Isles Lupus Assessment Group’s Disease Activity Index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44(7):902–6.

    CAS  Article  Google Scholar 

  38. Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999;42(7):1354–60.

    CAS  PubMed  Article  Google Scholar 

  39. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–12.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol. 2000;27(2):373–6.

    CAS  PubMed  Google Scholar 

  41. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther. 2012;14(Suppl 4):S4.

    PubMed  PubMed Central  Article  Google Scholar 

  42. Wallace DJ. The history of antimalarials. Lupus. 1996;5(Suppl 1):S2–3.

    PubMed  Article  Google Scholar 

  43. Lafyatis R, Marshak-Rothstein A. Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther. 2007;9(6):222.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  44. Dörner T. Therapy: Hydroxychloroquine in SLE: old drug, new perspectives. Nat Rev Rheumatol. 2010;6(1):10–1.

    PubMed  Article  CAS  Google Scholar 

  45. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324(3):150–4.

  46. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senécal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus: the Canadian Hydroxychloroquine Study Group. Lupus. 1998;7(2):80–5.

    CAS  PubMed  Article  Google Scholar 

  47. Pons-Estel GJ, Alarcón GS, McGwin G, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012;51(7):1145–53.

    CAS  Article  Google Scholar 

  49. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–23.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009;36(3):560–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009;48(6):673–5.

    Article  Google Scholar 

  52. Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol. 2010;63(4):288–95.

    CAS  PubMed  Article  Google Scholar 

  53. Winkelmann RR, Kim GK, Del Rosso JQ. Treatment of cutaneous lupus erythematosus: review and assessment of treatment benefits based on Oxford Centre for Evidence-Based Medicine criteria. J Clin Aesthet Dermatol. 2013;6(1):27–38.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR Standing Committee for Clinical Affairs. Ann Rheum Dis. 2010;69(12):2074–82.

    CAS  PubMed  Article  Google Scholar 

  55. Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014;23(3):225–35.

    CAS  PubMed  Article  Google Scholar 

  56. Ravelli A, Ballardini G, Viola S, Villa I, Ruperto N, Martini A. Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus. J Rheumatol. 1998;25(3):572–5.

    CAS  PubMed  Google Scholar 

  57. Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis. 2004;63(3):321–3.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375–83.

    PubMed  PubMed Central  Article  Google Scholar 

  59. Cattran DC, Feehally J, Cook HT, Liu Z-H, Fervenza FC, Mezzano SA, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.

  60. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–82.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. Sundel R, Solomons N, Lisk L, Group ALMSA. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus. 2012;21(13):1433–43.

    CAS  PubMed  Article  Google Scholar 

  62. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol. 2001;28(9):2103–8.

    CAS  PubMed  Google Scholar 

  63. Kizawa T, Nozawa T, Kikuchi M, Nagahama K, Okudela K, Miyamae T, et al. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis. Mod Rheumatol. 2015;25(2):210–4.

    CAS  PubMed  Article  Google Scholar 

  64. Lehman TJ, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB, et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr. 1989;114(6):1055–60.

    CAS  PubMed  Article  Google Scholar 

  65. Vachvanichsanong P, Dissaneewate P, McNeil E. Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis. Int Urol Nephrol. 2013;45(5):1301–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. Lehman TJ, Singh C, Ramanathan A, Alperin R, Adams A, Barinstein L, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J. 2014;12:3.

    PubMed  PubMed Central  Article  Google Scholar 

  67. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, EeR Garrido Ed, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121–31.

    CAS  PubMed  Article  Google Scholar 

  68. Silva CA, Brunner HI. Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus. Lupus. 2007;16(8):593–9.

    CAS  PubMed  Article  Google Scholar 

  69. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 2000;9(6):401–5.

    CAS  PubMed  Article  Google Scholar 

  70. Brunner HI, Silva CA, Reiff A, Higgins GC, Imundo L, Williams CB, et al. Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(5):1377–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  71. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188–95.

    CAS  PubMed  Google Scholar 

  72. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–806.

    CAS  PubMed  Article  Google Scholar 

  73. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol. 2007;179(5):3351–61.

    CAS  PubMed  Article  Google Scholar 

  74. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  75. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–26.

    CAS  PubMed  Article  Google Scholar 

  76. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med. 1996;125(7):549–57.

    CAS  PubMed  Article  Google Scholar 

  77. Uribe AG, McGwin G, Reveille JD, Alarcón GS. What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. Nurture) cohort? Where are we heading? Autoimmun Rev. 2004;3(4):321–9.

    PubMed  Article  Google Scholar 

  78. Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24(1):10–7.

    CAS  PubMed  Article  Google Scholar 

  79. Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child. 2008;93(5):401–6.

    CAS  PubMed  Article  Google Scholar 

  80. Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr. 2006;148(5):623–7.

    CAS  PubMed  Article  Google Scholar 

  81. Stohl W. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep. 2012;14(4):303–9.

    CAS  PubMed  Article  Google Scholar 

  82. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs. 2010;70(5):529–40.

    CAS  PubMed  Article  Google Scholar 

  83. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231–64.

    CAS  PubMed  Article  Google Scholar 

  84. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood. 2008;111(5):2755–64.

    CAS  PubMed  Article  Google Scholar 

  85. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453–9.

    CAS  PubMed  Article  Google Scholar 

  86. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31.

    CAS  PubMed  Article  Google Scholar 

  87. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30.

    CAS  PubMed  Article  Google Scholar 

  88. Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144–54.

    CAS  PubMed  Article  Google Scholar 

  89. Chang C, Pitukcheewanont P. Bone health in juvenile-onset systemic lupus erythematosus. Curr Rheumatol Rev. 2012;8:199–208.

    Article  Google Scholar 

  90. Lilleby V, Lien G, Frey Frøslie K, Haugen M, Flatø B, Førre Ø. Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2005;52(7):2051–9.

    PubMed  Article  Google Scholar 

  91. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515–26.

    PubMed  Article  Google Scholar 

  92. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292(4):490–5.

    CAS  PubMed  Article  Google Scholar 

  93. Maldonado-Gonzales E, Pietschmann P. An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases. Wien Med Wochenschr. 2010;160(17–18):458–63.

    PubMed  Article  Google Scholar 

  94. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58(5):1299–309.

    CAS  PubMed  Article  Google Scholar 

  95. Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2010;62(4):569–74.

    CAS  PubMed  Article  Google Scholar 

  96. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ. 2000;320(7227):79–82.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  97. Kreeftmeijer-Vegter AR, de Boer A, van der Vlugt-Meijer RH, de Vries PJ. The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children. Orphanet J Rare Dis. 2014;9:120.

    PubMed  PubMed Central  Article  Google Scholar 

  98. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48(3):719–27.

    CAS  PubMed  Article  Google Scholar 

  99. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008;58(8):2470–80.

    CAS  PubMed  Article  Google Scholar 

  100. van Vollenhoven RF. Challenges and opportunities in SLE clinical trials. Curr Opin Rheumatol. 2013;25(5):606–15.

    PubMed  Article  CAS  Google Scholar 

  101. Tudur Smith C, Williamson PR, Beresford MW. Methodology of clinical trials for rare diseases. Best Pract Res Clin Rheumatol. 2014;28(2):247–62.

  102. Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74(9):1667–75.

    CAS  PubMed  Article  Google Scholar 

  103. Genovese MC, Bojin S, Biagini IM, Mociran E, Cristei D, Mirea G, et al. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2013;65(4):880–9.

    CAS  PubMed  Article  Google Scholar 

  104. Genovese MC, Fleischmann RM, Greenwald M, Satterwhite J, Veenhuizen M, Xie L, et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013;72(9):1461–8.

    CAS  PubMed  Article  Google Scholar 

  105. Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  106. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006–15.

    PubMed  PubMed Central  Article  Google Scholar 

  107. Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford). 2013;52(7):1313–22.

    CAS  Article  Google Scholar 

  108. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73(1):183–90.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  109. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368–79.

    CAS  PubMed  Article  Google Scholar 

  110. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(10):3077–87.

    CAS  PubMed  Article  Google Scholar 

  111. Zimmer R, Scherbarth HR, Rillo OL, Gomez-Reino JJ, Muller S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013;72(11):1830–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  112. Zimmer R, Wallace D, Muller S. Randomized, double-blind, placebo-controlled studies of P140 peptide in mannitol (Lupuzor) and trehalose (forigerimod) in patients with SLE. Arthritis Rheum. 2012;64:S1110.

    Article  CAS  Google Scholar 

  113. Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65(4):1011–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  114. Kalunian K, Merrill J, Maciuca R, Ouyang R, McBride W, Townsend J, et al. Efficacy and safety of rontalizumab (anti-interferon alpha) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo-controlled phase 2 study. Arthritis Rheum. 2012;64(Suppl 10):2622.

    Google Scholar 

  115. McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012;64(11):3666–76.

    CAS  PubMed  Article  Google Scholar 

  116. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–52.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Women’s and Children’s Health, Institute of Translational Medicine, University of Liverpool, Institute in the Park, Alder Hey Children’s NHS Foundation Trust Hospital, Eaton Road, Liverpool, L12 2AP, UK

    Colin Thorbinson, Louise Oni, Eve Smith, Angela Midgley & Michael W. Beresford

Authors
  1. Colin Thorbinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louise Oni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eve Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angela Midgley
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael W. Beresford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael W. Beresford.

Ethics declarations

Funding

No sources of funding were used to support the writing of this manuscript.

Conflict of interest

Colin Thorbinson, Louise Oni, Eve Smith, Angela Midgley and Michael W. Beresford report no conflicts of interest that are directly relevant to the content of this article.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Thorbinson, C., Oni, L., Smith, E. et al. Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus. Pediatr Drugs 18, 181–195 (2016). https://doi.org/10.1007/s40272-016-0170-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-016-0170-8

Keywords

  • Systemic Lupus Erythematosus
  • Lupus Nephritis
  • Chronic Fatigue Syndrome
  • Mycophenolate Mofetil
  • Hydroxychloroquine